PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515376
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515376
Viral Vector Production Market size was valued at USD 1,298.43 Million in 2023, expanding at a CAGR of 17.5% from 2024 to 2032.
Genetically engineered viral vectors serve as vehicles to deliver specific genes or genetic material into cells, playing a vital role in biotechnology and gene therapy. Their primary functions include introducing therapeutic genes, rectifying genetic abnormalities, and modulating cellular functions. Adenoviruses (AdV), adeno-associated viruses (AAV), lentiviruses, retroviruses, among others, constitute the common types of viral vectors utilized in biotechnology. Adenoviral vectors, originating from adenoviruses responsible for human respiratory illnesses, and AAV vectors, derived from non-pathogenic viruses reliant on co-infection with helper viruses like adenoviruses for replication, are prominent examples. These versatile vectors find extensive applications across the biotechnology and pharmaceutical sectors, catalyzing significant advancements in gene therapy and biotechnological research. They have transformed these domains, facilitating the creation of innovative treatments and tools for elucidating and controlling genetic mechanisms.
Viral Vector Production Market- Market Dynamics
Rise in prevalence of cancer, infectious diseases, and genetic disorders to propel market demand
The surge in the prevalence of cancer, infectious diseases, and genetic disorders has profoundly influenced the market landscape. The escalating burden of these conditions has sparked a surge in demand for innovative therapies, notably gene therapy. Consequently, there's a corresponding uptick in the need for viral vectors to facilitate the development and manufacturing of gene therapies, as the prevalence of these ailments continues to climb. This trend has propelled the expansion of the viral vector production market. Moreover, the adoption of strategic maneuvers within the viral vector production market has further fueled its growth trajectory. Companies are deploying diverse strategies to bolster efficiency, expand production capacity, and enhance cost-effectiveness. By implementing these strategies, viral vector production firms can effectively meet the escalating demand for viral vectors, optimize production processes, and curtail manufacturing costs. These efforts are expected to underpin the continued growth of the market.
Viral Vector Production Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 17.5% over the forecast period (2024-2032)
Based on Vector Type segmentation, adeno-associated viruses were predicted to show maximum market share in the year 2023
Based on Indication segmentation, cancer was the leading type in 2023
Based on region, North America was the leading revenue generator in 2023
The Global Viral Vector Production Market is segmented based on Vector Type, Application, Indication, and Region.
The market is divided into five categories based on Vector Type: Adenoviral Vectors, Lentiviral Vectors, Retroviral Vectors, Adeno-Associated Viral Vectors and Other Viral Vectors. The adeno-associated viruses (AAV) vectors segment emerged as the dominant player in the viral vector production market, primarily driven by soaring demand in the gene therapy sector. According to the Alliance for Regenerative Medicine (ARM), AAV vectors constituted the primary vector used in gene therapy clinical trials, thereby fueling significant growth in this segment.
The market is divided into four categories based on Indication: Cancer, Genetic Disorders, Infectious Diseases and Other Diseases. In terms of indication, the cancer segment claimed the lion's share of the market revenue in 2023, owing to the pervasive prevalence of cancer worldwide. Statistics from the National Cancer Institute indicate an increasing number of new cancer cases and deaths in the U.S. alone in 2020. This widespread incidence of cancer has propelled the demand for advanced therapies like gene therapy, consequently driving the need for viral vector production in the development and research of such therapies.
Viral Vector Production Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America emerged as a major stronghold in the viral vector production market in 2023 and is poised to sustain its dominance in the forecast period. This growth can be attributed to the robust and well-established biotechnology and pharmaceutical industry in the region, equipped with advanced infrastructure and expertise in gene therapy and viral vector production. Additionally, the presence of leading biotech and pharmaceutical companies, research institutions, and academic centers further contributes to market expansion. Moreover, North America benefits from substantial government support and funding for research and development in the field of gene therapy and advanced therapeutics, positioning the region at the forefront of innovation and expediting the commercialization of viral vector-based therapies.
In the Viral Vector Production market, companies employ various strategic initiatives such as partnerships, capacity expansion, and technological advancements to uphold their competitive edge. Collaborations with biotechnology firms, contract manufacturing organizations (CMOs), and academic research institutions provide access to specialized expertise, production facilities, and regulatory knowledge crucial for scalable viral vector manufacturing. These partnerships foster innovation in production processes, like suspension cell culture and transient transfection, enhancing viral vector yields and quality while reducing production costs and timelines. Additionally, ongoing capacity expansion endeavors ensure companies can meet the escalating demand for viral vectors in gene therapy, vaccine development, and cell therapy applications. Furthermore, investments in research and development enable the exploration of novel vector platforms, production technologies, and gene delivery strategies, augmenting the versatility and efficacy of viral vectors for therapeutic and research purposes. Through strategic partnerships and technological advancements, companies in the Viral Vector Production market fortify their market position, drive innovation, and contribute to advancements in biopharmaceuticals and regenerative medicine.
In July 2022, Takara Bio Inc. introduced a new Contract Development and Manufacturing Organization (CDMO) service utilizing a brain-tropic adeno-associated virus (AAV) vector called "CereAAV" for clients in the gene and cell therapy industry.
GLOBAL VIRAL VECTOR PRODUCTION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT
Danaher Corporation
TAKARA HOLDINGS INC.
Charles River Laboratories
Andelyn Biosciences
Thermo Fisher Scientific Inc.
Novartis AG
Avid Bioservices, Inc.
Lonza
FinVector O
Oxford Biomedica
Others